Serum bactericidal activity of colistin and azidothymidine combinations against mcr-1-positive colistin-resistant Escherichia coli
Gram-negative bacteria, especially Enterobacteriaceae, are the major cause both of community- and hospital-acquired urinary tract infections, which is worsened by the continuous emergence of antimicrobial resistance and a shortage of new antibiotics under development. The number of antimicrobial agents to treat infections caused by antimicrobial-resistant Enterobacteriaceae is limited, and the polymyxins such as colistin are considered the treatment of last resort [1].
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Maria Loose, Kurt G. Naber, Yanmin Hu, Anthony Coates, Florian M.E. Wagenlehner Source Type: research
More News: Antimicrobial Resistance | Drugs & Pharmacology | Gastroenteritis | Hospitals | Urinary Tract Infections